JPMorgan analyst Yang Huang initiated coverage of Ascentage Pharma (AAPG) with an Overweight rating and HK$52 price target The company’s Olverembatinib, having been approved for three CML ...

Baroness Harman said the “job is far from done towards ending women’s inequality” and promised Britain would play a “key role in standing up for the rights of all women and girls at a ...

Roni Kamhi, CEO BI Sky Global and COO of Innocan Pharma commented: "We are very pleased with our outstanding results and especially our strong revenue growth. At BI Sky Global we are clearly ...

Harriet Harman currently sits in the House of Lords after previously serving as an MP for Peckham for over 40 years. Foreign Secretary David Lammy has today appointed Harriet Harman as the new UK ...

Sun Pharma has agreed to purchase the Massachusetts biotech for an upfront value of $355 million, or $4.10 per share, the companies said Sunday. With Unloxcyt, an FDA-approved PD-L1 therapy for ...

BERLIN, March 28, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment ...

Traws Pharma (TRAW) announced the retirement of Werner Cautreels, CEO, effective on or about close of business on March 31 after the company files its annual report on Form 10-K with the SEC.

March 10 (Reuters) - India's Sun Pharmaceutical Industries (SUN.NS), opens new tab said on Monday it will acquire Checkpoint Therapeutics (CKPT.O), opens new tab, a U.S.-based immunotherapy and ...

It demands significant resources that are often expensive and inaccessible to biotechnology and pharmaceutical companies of all sizes. Federal regulations like the Current Good Manufacturing ...

“Ireland has our pharma companies,” said US president Donald Trump on Wednesday in some of the most significant comments of his encounter with Taoiseach Micheál Martin. And he wants them bac ...

LabVantage Pharma is the only pre-configured and pre-validated pharmaceutical LIMS in the world. This greatly lowers the deployment cost (85%) and time (75%) compared to a traditional LIMS ...

In his March 17 op-ed, “We should stop acting as if Big Pharma is the big villain in American health care,” Erick Erickson writes, “The government cannot provide clarity or direction for ...